Nagalla Srikanth, Sarode Ravindra
Division of Hematology/Oncology, UT Southwestern Medical Center, Dallas, TX, USA.
Division of Transfusion Medicine and Hemostasis, Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA.
F1000Res. 2018 Jan 17;7:68. doi: 10.12688/f1000research.12309.1. eCollection 2018.
There are numerous congenital and acquired causes of thrombocytopenia. Thrombocytopenia could be a result of decreased bone marrow production, increased consumption, increased destruction, splenic sequestration or a combination of these causes. In this review, we have focused on some of the serious acquired causes of thrombocytopenia. There have been some significant advances in our understanding of the pathophysiology, diagnostic testing, and treatment of immune thrombocytopenia, heparin-induced thrombocytopenia, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome over the past five years. These advances have resulted in a significant decrease in mortality and morbidity of patients with these disorders. Despite these advances, we are still faced with numerous unanswered questions in the pathophysiology and management of these complex thrombocytopenic disorders.
血小板减少症有众多先天性和后天性病因。血小板减少症可能是骨髓生成减少、消耗增加、破坏增加、脾内滞留或这些病因共同作用的结果。在本综述中,我们重点关注了血小板减少症的一些严重后天性病因。在过去五年中,我们对免疫性血小板减少症、肝素诱导的血小板减少症、血栓性血小板减少性紫癜和非典型溶血性尿毒症综合征的病理生理学、诊断检测及治疗的认识取得了一些重大进展。这些进展已使这些疾病患者的死亡率和发病率显著降低。尽管有这些进展,但在这些复杂血小板减少性疾病的病理生理学和管理方面,我们仍面临众多未解答的问题。